# A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

> **NCT06113328** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 169 (actual)

## Conditions studied

- Non-segmental Vitiligo

## Interventions

- **BIOLOGICAL:** MK-6194
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06113328
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-11-27
- **Primary completion:** 2025-03-20
- **Final completion:** 2025-07-30
- **Target enrollment:** 169 (ACTUAL)
- **Why stopped:** Business Reasons
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06113328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06113328, "A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06113328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*